Ameriprise’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ameriprise’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-52,572	Closed	-$79.4K	–	4232
2025 Q3	$79.4K	Sell	52,572 -38,623	-42%	-$57.9K	﹤0.01%	3989
2025 Q2	$106K	Buy	91,195 +78,578	+623%	+$104K	﹤0.01%	3879
2025 Q1	$20.1K	Sell	12,617 -134,056	-91%	-$289K	﹤0.01%	3983
2024 Q4	$444K	Buy	+146,673	New	+$481K	﹤0.01%	3568
2023 Q4	–	Sell	-166,004	Closed	-$3.33M	–	3991
2023 Q3	$3.33M	Sell	166,004 -36,675	-18%	-$931K	﹤0.01%	2573
2023 Q2	$5.72M	Sell	202,679 -64,626	-24%	-$1.55M	﹤0.01%	2240
2023 Q1	$4.6M	Buy	267,305 +48,341	+22%	+$979K	﹤0.01%	2382
2022 Q4	$4.41M	Buy	218,964 +34,515	+19%	+$742K	﹤0.01%	2372
2022 Q3	$3.99M	Buy	184,449 +10,905	+6%	+$298K	﹤0.01%	2373
2022 Q2	$4.88M	Buy	+173,544	New	+$4.6M	﹤0.01%	2297

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise's ZNTL Position: Q4 2025 in Review

Ameriprise sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 52,572 shares — an estimated $79.4K sold.

Ameriprise first reported a position in ZNTL in Q2 2022 and held it in 10 quarters. The position peaked at $5.72M in Q2 2023. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

Ameriprise reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Ameriprise sold 52,572 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $79.4K.
Ameriprise first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 10 quarters.
Ameriprise's Zentalis Pharmaceuticals position peaked at $5.72M in Q2 2023.
86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.